Rare disease drugmaker · based in Ponte Vedra Beach, United States · founded 2022 · ticker CVKD · cadrenal.com
Cadrenal Therapeutics works on Heparin-Induced Thrombocytopenia, one of the rare diseases we track.
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic (blood clotting) conditions.
Cadrenal Therapeutics clinical trials
We did not find active Cadrenal Therapeutics trials for the rare diseases we track on ClinicalTrials.gov right now.
Follow a condition Cadrenal Therapeutics is studying
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Cadrenal Therapeutics. Unsubscribe anytime.
You'll get, for Heparin-Induced Thrombocytopenia:
Trial Alerts, when a new trial opens or a trial changes
Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
The lead program, CAD-1005, is a first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT), a deadly immune-mediated reaction where the body's response to heparin causes dangerous clots. Mortality from HIT can exceed 20% in some studies. Cadrenal says that, if approved, CAD-1005 would be the first new HIT therapy in more than 2 decades.
On April 30, 2026, Cadrenal announced a successful End-of-Phase 2 meeting with the FDA and a clear Phase 3 path. Cadrenal reported that Phase 2 data showed a more than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy.
The planned Phase 3 trial is randomized, blinded, and placebo-controlled in approximately 120 patients across up to 50 sites worldwide, with a projected NDA submission in 2029. CAD-1005 holds FDA Orphan Drug and Fast Track designations and orphan drug status from the European Medicines Agency.
The broader pipeline includes tecarfarin, a late-stage oral blood thinner being developed for patients who need long-term anticoagulation (including those on dialysis or living with a left ventricular assist device), and frunexian, a parenteral Factor XIa inhibitor for use in acute hospital settings.
Rare diseases Cadrenal Therapeutics works on
Each disease page lists every open trial, not only Cadrenal Therapeutics's, plus approved treatments.
Heparin-induced thrombocytopenia is a serious immune-mediated reaction to heparin, one of the most commonly used blood thinners in hospitals.
How common: Occurs in approximately 0.5-5% of patients exposed to heparin, depending on the type and duration of heparin used and the clinical setting
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Cadrenal Therapeutics's own site is cadrenal.com, and our help paying for treatment page lists drugmaker programs and charity funds.
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic (blood clotting) conditions.
The lead program, CAD-1005, is a first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT), a deadly immune-mediated reaction where the body's response to heparin causes dangerous clots. Mortality from HIT can exceed 20% in some studies. Cadrenal says that, if approved, CAD-1005 would be the first new HIT therapy in more than 2 decades.
On April 30, 2026, Cadrenal announced a successful End-of-Phase 2 meeting with the FDA and a clear Phase 3 path. Cadrenal reported that Phase 2 data showed a more than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy. The planned Phase 3 trial is randomized, blinded, and placebo-controlled in approximately 120 patients across up to 50 sites worldwide, with a projected NDA submission in 2029. CAD-1005 holds FDA Orphan Drug and Fast Track designations and orphan drug status from the European Medicines Agency.
The broader pipeline includes tecarfarin, a late-stage oral blood thinner being developed for patients who need long-term anticoagulation (including those on dialysis or living with a left ventricular assist device), and frunexian, a parenteral Factor XIa inhibitor for use in acute hospital settings.
Cadrenal Therapeutics has active programs across 1 rare disease: Heparin-Induced Thrombocytopenia. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.
Yes. Cadrenal Therapeutics is a rare disease specialist headquartered in Ponte Vedra Beach, United States, founded in 2022. The company focuses primarily on developing treatments for rare and orphan diseases, with programs targeting Heparin-Induced Thrombocytopenia.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Cadrenal Therapeutics, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
None as of November 2026. Cadrenal Therapeutics has no FDA-approved drug yet; its programs are still in trials.
Where to watch: the FDA calendar lists any Cadrenal Therapeutics application once a decision date is public, and the trials list on this page shows what is recruiting now.
Cadrenal Therapeutics was founded in 2022 and is headquartered in Ponte Vedra Beach, United States. The company has been active for 4 years. It trades publicly under the ticker symbol CVKD. As a rare disease specialist, the company dedicates its resources to developing therapies for patients with rare and orphan conditions.